Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 20-Nov-24 4:20 PM View:  | Mehra Anand Director | Aclaris Therapeutics, Inc. (ACRS) | 19-Nov-24 | Private Purchase | 666,666 | $2.25 | $1,500,000.00 | 1537% 43.36K to 710.03K | |
| 04-Sep-24 5:08 PM View: | Walker Neal Interim President and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Sep-24 | Payment of Exercise | 2,722 | $1.18 | $3,211.96 | (< 1%) 1.37M to 1.36M | |
| 04-Sep-24 7:52 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Sep-24 | Payment of Exercise | 286 | $1.18 | $337.48 | (1%) 24.98K to 24.7K | |
| 04-Sep-24 5:08 PM View: | Walker Neal Interim President and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Sep-24 | Option Exercise | 9,466 | -- | -- | < 1% 1.36M to 1.37M | |
| 04-Sep-24 7:52 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Sep-24 | Option Exercise | 1,000 | -- | -- | 4% 23.98K to 24.98K | |
| 13-Aug-24 4:15 PM View: | Walker Neal Interim President and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 09-Aug-24 | Option Exercise | 43,548 | $0.72 | $31,354.60 | 3% 1.31M to 1.36M | |
| 05-Aug-24 3:57 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 05-Aug-24 | Purchase | 206,025 | $1.24 | $256,357.00 | < 1% 28.09M to 28.29M | |
| 05-Aug-24 3:57 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 02-Aug-24 | Private Purchase | 167,544 | $1.29 | $216,400.00 | < 1% 27.92M to 28.09M | |
| 05-Aug-24 4:15 PM View: | Walker Neal Interim President and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Aug-24 | Option Exercise | 9,467 | -- | -- | < 1% 1.31M to 1.32M | |
| 05-Aug-24 4:15 PM View: | Walker Neal Interim President and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Aug-24 | Payment of Exercise | 2,722 | $1.32 | $3,593.04 | (< 1%) 1.32M to 1.31M | |
| 31-Jul-24 4:10 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 31-Jul-24 | Purchase | 100,000 | $1.33 | $132,640.00 | < 1% 27.55M to 27.65M | |
| 31-Jul-24 4:10 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 30-Jul-24 | Private Purchase | 173,730 | $1.30 | $226,370.00 | < 1% 27.38M to 27.55M | |
| 22-Jul-24 4:03 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 22-Jul-24 | Purchase | 17,716 | $1.33 | $23,557.00 | < 1% 27.16M to 27.18M | |
| 22-Jul-24 4:03 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 19-Jul-24 | Purchase | 6,689 | $1.30 | $8,695.70 | < 1% 27.16M to 27.16M | |
| 22-Jul-24 4:03 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 18-Jul-24 | Private Purchase | 130,317 | $1.30 | $169,555.00 | < 1% 27.03M to 27.16M | |
| 05-Jul-24 2:46 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 05-Jul-24 | Purchase | 123,017 | $1.15 | $141,334.00 | < 1% 26.51M to 26.63M | |
| 05-Jul-24 2:46 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 03-Jul-24 | Purchase | 143,288 | $1.16 | $166,071.00 | < 1% 26.36M to 26.51M | |
| 05-Jul-24 2:46 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 02-Jul-24 | Private Purchase | 86,092 | $1.14 | $98,489.20 | < 1% 26.28M to 26.36M | |
| 01-Jul-24 1:39 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 01-Jul-24 | Purchase | 107,434 | $1.14 | $122,185.00 | < 1% 24.78M to 24.88M | |
| 01-Jul-24 1:39 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 28-Jun-24 | Purchase | 1,201,000 | $1.12 | $1,348,560.00 | 5% 23.57M to 24.78M | |
| 01-Jul-24 1:39 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 27-Jun-24 | Private Purchase | 235,000 | $1.15 | $271,331.00 | 1% 23.34M to 23.57M | |
| 18-Jun-24 4:04 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 18-Jun-24 | Purchase | 50,000 | $1.13 | $56,505.00 | < 1% 22.85M to 22.9M | |
| 18-Jun-24 4:04 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 17-Jun-24 | Purchase | 150,000 | $1.13 | $169,500.00 | < 1% 22.7M to 22.85M | |
| 18-Jun-24 4:04 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 14-Jun-24 | Private Purchase | 345,000 | $1.17 | $402,201.00 | 2% 22.36M to 22.7M | |
| 13-Jun-24 6:04 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 13-Jun-24 | Purchase | 528,621 | $1.15 | $607,757.00 | 5% 10.48M to 11.01M | |
| 13-Jun-24 6:04 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 12-Jun-24 | Purchase | 82,579 | $1.14 | $94,140.10 | < 1% 10.4M to 10.48M | |
| 13-Jun-24 6:04 PM View: | Leonard Braden Michael 10% Owner | Aclaris Therapeutics, Inc. (ACRS) | 11-Jun-24 | Private Purchase | 1,000,000 | $1.08 | $1,080,000.00 | 11% 9.4M to 10.4M | |
| 04-Jun-24 4:30 PM View: | Reasons Bryan M. Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Jun-24 | Option Exercise | 4,660 | -- | -- | 19% 24.07K to 28.73K | |
| 04-Jun-24 4:30 PM View: | Walker Neal Interim President and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Jun-24 | Option Exercise | 9,466 | -- | -- | < 1% 1.29M to 1.3M | |
| 04-Jun-24 4:30 PM View: | Humphries William D. Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Jun-24 | Option Exercise | 4,660 | -- | -- | 19% 24.07K to 28.73K | |
| 04-Jun-24 4:30 PM View: | Mehra Anand Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Jun-24 | Option Exercise | 4,660 | -- | -- | 12% 38.7K to 43.36K | |
| 04-Jun-24 4:30 PM View: | Powell Andrew Kenneth William Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Jun-24 | Option Exercise | 4,660 | -- | -- | 16% 28.86K to 33.52K | |
| 04-Jun-24 4:30 PM View: | Walker Neal Interim President and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Jun-24 | Payment of Exercise | 2,722 | $1.03 | $2,803.66 | (< 1%) 1.3M to 1.3M | |
| 04-Jun-24 4:30 PM View: | Molineaux Christopher P. Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Jun-24 | Option Exercise | 4,660 | -- | -- | 10% 48.5K to 53.16K | |
| 04-Jun-24 4:30 PM View: | Gowen Maxine Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Jun-24 | Option Exercise | 4,660 | -- | -- | 38% 12.3K to 16.96K | |
| 04-Jun-24 4:30 PM View: | Milano Vincent Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Jun-24 | Option Exercise | 4,660 | -- | -- | 59% 7.86K to 12.52K | |
| 04-Jun-24 4:30 PM View: | Schiff Dr Drew Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Jun-24 | Option Exercise | 4,660 | -- | -- | 1% 438.96K to 443.62K | |
| 03-May-24 4:20 PM View: | Walker Neal Interim President and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-May-24 | Payment of Exercise | 2,784 | $1.26 | $3,507.84 | (< 1%) 1.3M to 1.29M | |
| 03-May-24 4:20 PM View: | Walker Neal Interim President and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-May-24 | Option Exercise | 9,467 | -- | -- | < 1% 1.29M to 1.3M | |
| 03-Apr-24 5:00 PM View: | Walker Neal Interim President and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Apr-24 | Payment of Exercise | 3,224 | $1.26 | $4,062.24 | (< 1%) 1.29M to 1.29M | |
| 03-Apr-24 5:00 PM View: | Walker Neal Interim President and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Apr-24 | Option Exercise | 9,467 | -- | -- | < 1% 1.28M to 1.29M | |
| 05-Mar-24 4:58 PM View: | Powell Andrew Kenneth William Director | Aclaris Therapeutics, Inc. (ACRS) | 04-Mar-24 | Purchase | 6,000 | $1.25 | $7,500.00 | 26% 22.86K to 28.86K | |
| 05-Mar-24 5:02 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 02-Mar-24 | Payment of Exercise | 427 | $1.24 | $529.48 | (2%) 24.41K to 23.98K | |
| 05-Mar-24 5:02 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 02-Mar-24 | Option Exercise | 1,500 | -- | -- | 7% 22.91K to 24.41K | |
| 05-Mar-24 5:04 PM View: | Monahan Joseph Chief Scientific Officer | Aclaris Therapeutics, Inc. (ACRS) | 02-Mar-24 | Payment of Exercise | 3,531 | $1.24 | $4,378.44 | (2%) 190.51K to 186.98K | |
| 05-Mar-24 5:04 PM View: | Monahan Joseph Chief Scientific Officer | Aclaris Therapeutics, Inc. (ACRS) | 02-Mar-24 | Option Exercise | 12,500 | -- | -- | 7% 178.01K to 190.51K | |
| 05-Mar-24 5:08 PM View: | Walker Neal Interim President and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Mar-24 | Payment of Exercise | 3,223 | $1.24 | $3,996.52 | (< 1%) 1.28M to 1.28M | |
| 05-Mar-24 5:08 PM View: | Walker Neal Interim President and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Mar-24 | Option Exercise | 9,466 | -- | -- | < 1% 1.27M to 1.28M | |
| 05-Mar-24 5:02 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Mar-24 | Payment of Exercise | 990 | $1.24 | $1,227.60 | (4%) 23.9K to 22.91K | |
| 05-Mar-24 5:02 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Mar-24 | Option Exercise | 3,475 | -- | -- | 17% 20.43K to 23.9K |
